---
layout: post
title: "Human Gene Therapy for Retinal Disorders; Guidance for Industry; Availability"
date: 2026-02-05 19:08:19 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2020-01703
original_published: 2020-01-30 00:00:00 +0000
significance: 8.00
---

# Human Gene Therapy for Retinal Disorders; Guidance for Industry; Availability

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** January 30, 2020 00:00 UTC
**Document Number:** 2020-01703

## Summary

The Food and Drug Administration is announcing the availability of a final guidance entitled "Human Gene Therapy for Retinal Disorders; Guidance for Industry." The final guidance provides recommendations to stakeholders developing human gene therapy (GT) products for retinal disorders affecting adult and pediatric patients. The guidance focuses on issues specific to GT products for retinal disorders and provides recommendations related to product development, preclinical testing, and clinical trial design for such GT products. The guidance announced in this notice finalizes the draft guidance of the same title dated July 2018.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/01/30/2020-01703/human-gene-therapy-for-retinal-disorders-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2020-01703

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
